Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.51 |
| ▸ | NOS2 | P35228 | 4/20 | 0.51 |
| ▸ | NOS1 | P29475 | 3/20 | 0.51 |
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.42 |
| ▸ | GABRE | P78334 | 2/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25220483 | 0.83 | LOXL2 (0.39) | NOS3NOS2NOS1LOXLOXL2 | |
| SCHEMBL501356 | 0.82 | GRM5 (0.41) | NOS3NOS2NOS1DYRK1ALOX | |
| SCHEMBL1166695 | 0.82 | LOX (0.34) | NOS3NOS2NOS1LOXLOXL2 | |
| SCHEMBL30542327 | 0.81 | LOXL2 (0.47) | LOXL2AAK1 | |
| SCHEMBL1766223 | 0.81 | RECQL (0.47) | LOXLOXL2AAK1 | |
| SCHEMBL29411261 | 0.81 | RECQL (0.47) | LOXLOXL2AAK1 | |
| SCHEMBL31139328 | 0.81 | BACE1 (0.34) | LOXLOXL2 | |
| SCHEMBL2889185 | 0.81 | LOXL2 (0.47) | LOXL2AAK1 | |
| SCHEMBL21068406 | 0.79 | RECQL (0.35) | S1PR1S1PR3 | |
| SCHEMBL30464975 | 0.79 | RECQL (0.35) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777710-A | Polymer elastomer with excellent mechanical properties and preparation method thereof | 广东安拓普聚合物科技股份有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-4630115-A1 | THERAPEUTIC COMPOUNDS | Sanofi (FR) | 2025-10-15 | — | — | EP | disclosed |
| CN-118724916-A | Polyaryl-containing macrocyclic compounds and uses thereof | 浙江养生堂天然药物研究所有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024121427-A1 | THERAPEUTIC COMPOUNDS | SANOFI (FR) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024121427-A1 | THERAPEUTIC COMPOUNDS | SANOFI (FR) | 2024-06-13 | — | — | WO | disclosed |
| US-20240190823-A1 | NRF2 INHIBITORS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2024-06-13 | — | — | US | disclosed |
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-30 | — | — | US | disclosed |
| CN-117777710-A | Polymer elastomer with excellent mechanical properties and preparation method thereof | 广东安拓普聚合物科技股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-112204006-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-11-28 | — | — | CN | disclosed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-20040023981-A1 | Salt forms with tyrosine kinase activity | REN YU (US) | 2004-02-05 | — | — | US | disclosed |
| US-6586424-B2 | Anticancer agents; anticholesterol agents | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-6586423-B2 | 2-(Pyridin-2-ylamino)-thiazole-5-carbonitrile derivatives; angiogenesis inhibitors; antitumor and anticarcinogenic agents; atherosclerosis, macular degeneration, diabetic retinopathy | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030100567-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2003-05-29 | — | — | US | disclosed |
| US-20030064996-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
| WO-2003000687-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1218376-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020147203-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2002-10-10 | — | — | US | disclosed |
| EP-1218376-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001017995-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147203-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | NOS3 718/4885NOS2 895/4885NOS1 881/4885 |
| US-20040023981-A1 | Salt forms with tyrosine kinase activity | TEK, MAP3K1, MAP3K2 | NOS3 581/4885NOS2 771/4885NOS1 929/4885 |
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | NOS3 1413/4885NOS2 943/4885NOS1 1279/4885 |
| US-20030064996-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | NOS3 718/4885NOS2 895/4885NOS1 881/4885 |
| US-11773110-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | NOS3 270/4885NOS2 197/4885NOS1 544/4885 |
| US-20030100567-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | NOS3 718/4885NOS2 895/4885NOS1 881/4885 |
| US-20240190823-A1 | NRF2 INHIBITORS AND USES THEREOF | KEAP1, NFE2L2, NQO1 | NOS3 1440/4885NOS2 1579/4885NOS1 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.